Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RNA CART-cMET in Advanced Melanoma and Breast Carcinoma
NCT03060356Phase 1Terminated
- Sponsor
- University of Pennsylvania
- Start
- Dec 2016
- Primary completion
- Mar 2020
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of cMET CAR T cells in melanoma and breast carcinoma (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Number of participants with treatment-related adverse events at 4 months. Started Dec 2016; status: terminated.
02
Drugs
cMET CAR T cells
03
Conditions
melanomabreast carcinoma
Beyond the preview
Go deeper on NCT03060356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060356.